232 related articles for article (PubMed ID: 33776913)
21. Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.
Zúñiga D; Stumpf MAM; Monteiro ALS; Glezer A
J Endocrinol Invest; 2024 May; 47(5):1295-1303. PubMed ID: 37938428
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Felker J; Patterson B; Wrubel D; Janss A
J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961
[TBL] [Abstract][Full Text] [Related]
24. Phenotype and resistance patterns of 10 resistant prolactinomas.
Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
[TBL] [Abstract][Full Text] [Related]
25. Temozolomide in the management of dopamine agonist-resistant prolactinomas.
Whitelaw BC; Dworakowska D; Thomas NW; Barazi S; Riordan-Eva P; King AP; Hampton T; Landau DB; Lipscomb D; Buchanan CR; Gilbert JA; Aylwin SJ
Clin Endocrinol (Oxf); 2012 Jun; 76(6):877-86. PubMed ID: 22372583
[TBL] [Abstract][Full Text] [Related]
26. Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Ceccato F; Lombardi G; Albiger N; Mazzai L; Pambuku A; Rolma G; Zagonel V; Scaroni C
Anticancer Drugs; 2019 Jun; 30(5):533-536. PubMed ID: 30986806
[TBL] [Abstract][Full Text] [Related]
27. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
28. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
29. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
30. How effective is temozolomide for treating pituitary tumours and when should it be used?
Halevy C; Whitelaw BC
Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
[TBL] [Abstract][Full Text] [Related]
31. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
Bueno C; Trarbach EB; Bronstein MD; Glezer A
Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
[TBL] [Abstract][Full Text] [Related]
32. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
33. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
[TBL] [Abstract][Full Text] [Related]
34. Predictors of dopamine agonist resistance in prolactinoma patients.
Vermeulen E; D'Haens J; Stadnik T; Unuane D; Barbe K; Van Velthoven V; Gläsker S
BMC Endocr Disord; 2020 May; 20(1):68. PubMed ID: 32429916
[TBL] [Abstract][Full Text] [Related]
35. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
36. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
37. Dopamine Agonists: From the 1970s to Today.
Auriemma RS; Pirchio R; De Alcubierre D; Pivonello R; Colao A
Neuroendocrinology; 2019; 109(1):34-41. PubMed ID: 30852578
[TBL] [Abstract][Full Text] [Related]
38. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
[TBL] [Abstract][Full Text] [Related]
40. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
